{"url_path":"/sec/aort/8-k/2026-05-18/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/784199/0001628280-26-035798-index.html","accession_number":"0001628280-26-035798","cik":"0000784199","ticker":"AORT","issuer_name":"ARTIVION, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/784199/0001628280-26-035798-index.html","primary_entity_key":"0000784199","primary_entity_name":"ARTIVION, INC."},"word_count":118,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\nOn May 18, 2026, Artivion, Inc. (“Artivion”) issued a press release announcing the completion of the acquisition of Endospan Ltd. (“Endospan”), an Israeli corporation that designs, develops, markets and sells innovative products for the treatment of aortic instability, including the Nexus™ product. A copy of the press release is furnished as Exhibit 99.1 hereto. Such press release shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Artivion under the Securities Act of 1933, as amended, or the Exchange Act."}